GlassScriptPhysician profile
Stanley D Demorest
NPI 1982769071
$548.55
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $536 · 2020: $12.97.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $169.97 | 2019 | |
| Lilly USA, LLC | $82.75 | 2019-2020 | |
| Allergan, INC. | $77.26 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $45.04 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.71 | 2019 | |
| Sunovion Pharmaceuticals INC. | $31.03 | 2019 | |
| Pfizer INC. | $26.82 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $20.69 | 2019 | |
| Antares Pharma, INC. | $15.40 | 2019 | |
| Mylan Specialty L.P. | $14.25 | 2019 | |
| Horizon Therapeutics Plc | $13.13 | 2019 | |
| Aytu Biopharma, INC. | $11.50 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stanley Demorest listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.